RT Journal Article
SR Electronic
T1 Clinical and genomic signatures of rising SARS-CoV-2 Delta breakthrough infections in New York
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.07.21267431
DO 10.1101/2021.12.07.21267431
A1 Duerr, Ralf
A1 Dimartino, Dacia
A1 Marier, Christian
A1 Zappile, Paul
A1 Levine, Samuel
A1 François, Fritz
A1 Iturrate, Eduardo
A1 Wang, Guiqing
A1 Dittmann, Meike
A1 Lighter, Jennifer
A1 Elbel, Brian
A1 Troxel, Andrea B.
A1 Goldfeld, Keith S.
A1 Heguy, Adriana
YR 2021
UL http://medrxiv.org/content/early/2021/12/17/2021.12.07.21267431.abstract
AB In 2021, Delta has become the predominant SARS-CoV-2 variant worldwide. While vaccines effectively prevent COVID-19 hospitalization and death, vaccine breakthrough infections increasingly occur. The precise role of clinical and genomic determinants in Delta infections is not known, and whether they contribute to increased rates of breakthrough infections compared to unvaccinated controls. Here, we show a steep and near complete replacement of circulating variants with Delta between May and August 2021 in metropolitan New York. We observed an increase of the Delta sublineage AY.25, its spike mutation S112L, and nsp12 mutation F192V in breakthroughs. Delta infections were associated with younger age and lower hospitalization rates than Alpha. Delta breakthroughs increased significantly with time since vaccination, and, after adjusting for confounders, they rose at similar rates as in unvaccinated individuals. Our data indicate a limited impact of vaccine escape in favor of Delta’s increased epidemic growth in times of waning vaccine protection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGenomic surveillance for SARS-CoV-2 was supported by NYULH institutional funding. The NYULH Genome Technology Center is partially supported by the Cancer Center Support Grant P30CA016087 at the Laura and Isaac Perlmutter Cancer Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NYULH Institutional Review Board, protocol numbers i21-00493 and i21-00561.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequences are publicly available in SRA (BioProject PRJNA769411) and GISAID (Tables S1-S3).